Pharmacelsus and Insilico Biotechnology Combines to Deliver in Preclinical Drug Development Scenario
FREMONT, CA: Pharmacelsus, preclinical contract research organization (CRO) and Insilico Biotechnology, provider of innovative solutions around the simulation of biological processes, recently joined forces to improve their expertise in preclinical characterization of drug-candidates.
The partnership exploits the German based Pharmacelsus’ experimental expertise and Incilico's skills in the fields of modeling and simulation, providing end-to-end solutions for the testing of potential drugs. A minimum amount of empirical in vitro data is generated which are tan evaluated using computational models to predict the TEMPeffects of the API on the human body or the outcome of preclinical animal trials with high accuracy. The integrated approach brings down the required experimental effort, especially in animal testing, simplifies the selection of promising drug candidates, and reduces risk, time, and cost of the drug development process.
The portfolio comprises the prediction of pharmacokinetic properties and equivalent in vivo doses both in preclinical species and in humans on the basis of in vitro ADMET data. This allows customers to develop the optimal protocol for necessary animal studies. Additionally, customer’s challenging problems in research can be tackled applying the integrated noledge base in preclinical drug development, bioanalytics, modeling and simulation.
"The alliance with Pharmacelsus enables Insilico to offer new packages comprising experimental services and simulation solutions. Pharmacelsus is the ideal partner for this joint enterprise", says Klaus Mauch, CEO of Insilico. Dr. Christine Batzl-Hartmann, Pharmacelsus’ CEO, adds: "We are glad about the fact that the long-standing cooperation between Pharmacelsus and Insilico will now mount a combined service, and we are confident that this service will provide an aid in our customers’ preclinical research."
Check Out : TOP BIOTECH STARTUPS IN EUROPE